HeartFlow calls off plans to merge, go public due to ‘unfavorable market conditions’

HeartFlow, a California-based health technology company focused on cardiac care, is canceling its previously announced plan to merge with Longview Acquisition Corp. II and form a publicly traded company.

The decision is a result of “current unfavorable market conditions,” the company said in a statement.

The deal, originally announced back in July 2021, valued the combined entity — which would have gone by the name HeartFlow Group and been listed on the New York Stock Exchange as “HFLO” — at approximately $2.4 billion.

“We believe that our non-invasive, AI-enabled, cloud-based enterprise software solution can transform cardiovascular care with risk assessment, diagnosis planning and treatment management,” John H. Stevens, MD, president, CEO and co-founder of HeartFlow, said at the time. “Importantly, we have brought together a talented group of individuals with deep expertise in technology, cardiovascular medicine, and the business of healthcare and a deep commitment to patients to deliver on this vision.”

Heartflow offers a CT image-based algorithm to determine the fractional flow reserve (CT-FFR) of blood flow in the coronary arteries for the entire coronary tree. This non-invasive imaging method can help determine if a patient needs to got to the cath lab for revascularization or needs additional followup tests. It can also determine if a patient presenting to a hospital with chest pain can be discharged safely. CT-FFR can avoid the need for conventional catheter-based FFR wires inserted into the coronaries in an invasive cath lab procedure. The technology was included as a testing option in the 2021 chest pain imaging guidelines.

Related Cardiology Economics Content:

Judge dismisses cardiology practice’s $50M lawsuit against St. Louis health system

No Surprises Act takes effect, leading to a mix of cheers and jeers from heart specialists

Cardiologists report an average 2021 salary of $538K, up 2% from 2020, as pandemic continues

Michael Walter
Michael Walter, Managing Editor

Michael has more than 18 years of experience as a professional writer and editor. He has written at length about cardiology, radiology, artificial intelligence and other key healthcare topics.

Around the web

Ron Blankstein, MD, professor of radiology, Harvard Medical School, explains the use of artificial intelligence to detect heart disease in non-cardiac CT exams.

Eleven medical societies have signed on to a consensus statement aimed at standardizing imaging for suspected cardiovascular infections.

Kate Hanneman, MD, explains why many vendors and hospitals want to lower radiology's impact on the environment. "Taking steps to reduce the carbon footprint in healthcare isn’t just an opportunity," she said. "It’s also a responsibility."